BioControl secures £500,000

BioControl, a UK-based company developing a phage based treatment for pseudomonas aeruginosa infections, has raised £500,000 in its first institutional round.


BioControl, a UK-based company developing a phage based treatment for pseudomonas aeruginosa infections, has raised £500,000 in its first institutional round.

BioControl, a UK-based company developing a phage-based treatment for pseudomonas aeruginosa infections, has raised £500,000 in its first institutional round.

This comprised £250,000 from The Capital Fund and £250,000 from existing shareholders.

Pseudomonas is highly resistant to antibiotics; infections are persistent and can be lethal. Pseudomonas is a particular threat to cystic fibrosis sufferers. Biocontrol’s phage therapy has proved effective in phase two trials for topical applications. Biocontrol is now targeting the deep lung.

Patrick Benham-Crosswell of BC Capital, BioControl’s corporate finance adviser, said: “This investment enables BioControl to develop its therapy in preparation for wider trials. As the extent of pseudomonas infections becomes known, demand for Biocontrol’s phage-based therapies is likely to rise.”

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics